IgG Antibodies Directly Block Insulin Receptors in Fat Tissue Driving Metabolic Disease

The immunometabolic revolution has shifted focus from immune cell infiltration to soluble antibody-mediated mechanisms. This 2025 review by Kim et al. synthesizes emerging evidence that IgG—classically understood as a circulating immune effector—accumulates pathologically in adipose tissue and directly interferes with insulin signaling, offering a new mechanistic framework for obesity-linked and age-related metabolic disease.

The central discovery reviewed is that IgG selectively deposits in white adipose tissue via the neonatal Fc receptor (FcRn), reaching concentrations up to 16-fold above plasma levels in diet-induced obesity models. This selectivity—IgA and IgM do not accumulate comparably—points to an active, receptor-mediated process rather than passive extravasation. Using AI-assisted molecular modeling with experimental validation, researchers identified that the Fc CH3 domain of IgG physically interacts with the insulin receptor ectodomain, sterically blocking insulin binding without triggering broader receptor tyrosine kinase disruption. This direct competition represents a novel form of molecular mimicry distinct from cytokine-mediated insulin resistance.

IgG glycosylation status critically modulates these effects. Sialylated IgG engages anti-inflammatory receptors (DC-SIGN, CD22) and is metabolically protective, whereas hyposialylated IgG—predominant in obesity and aging—activates endothelial FcγRIIB receptors, impairs insulin transcytosis across vascular endothelium, and promotes vascular insulin resistance. This glycosylation-dependent dichotomy may explain why individuals with similar BMI can have very different metabolic profiles, supporting glycosylation profiling as a precision medicine biomarker.

The review proposes a temporal model distinguishing acute (obesity-driven, weeks) and chronic (aging-driven, years) phases. In early obesity, adipose progenitor cells upregulate FcRn to initiate IgG deposition; as obesity persists, infiltrating macrophages take over as the dominant FcRn source, creating a self-amplifying inflammatory-metabolic loop. In aging, the slower accumulation of IgG shifts outcomes from acute insulin resistance toward chronic tissue fibrosis via TGF-β and collagen deposition, mediated by tissue-resident macrophage FcRn expression. Critically, FcRn antagonists (including antisense oligonucleotides) have been shown to reverse insulin resistance in animal models, and restoring IgG sialylation using sialic acid precursors improves function without requiring antibody depletion.

The authors acknowledge important caveats: most mechanistic data derive from rodent models, the relative contributions of direct IgG-receptor interference versus Fc receptor-mediated inflammation remain incompletely resolved, and beneficial immunometabolic roles of certain antibody populations (natural IgM, regulatory T cell-associated mechanisms) mean that broad immune suppression strategies carry risks. This review integrates molecular, tissue-specific, and systemic evidence into a unified framework that reframes metabolic disease pathogenesis and opens new avenues for antibody-targeted therapies.